Regularização fundiária - nova lei - velhas práticas: caso de araguaína – amazônia legal.

O estudo realizado objetivou, a partir da análise em assentamentos humanos de baixa renda, entender a segregação periférica e a expansão urbana na cidade de Araguaína-TO. A metodologia de abordagem qualitativa aplicada ao estudo consistiu na análise de documentos sobre os programas habitacionais e os de regularização fundiária, elaborados pelo Poder Público local. Realizou-se pesquisa de campo nos assentamentos humanos de baixa renda definidos pelo estudo. Este trabalho de campo, que consistiu em entrevistas com as lideranças das ocupações estudadas e com os gestores municipais, teve a finalidade de compreender os modos de ocupação irregular na cidade, pela lógica da demanda por moradia e disputa do espaço urbano, entendido como mercadoria pelo setor imobiliário. Concluiu-se haver problema fundiário complexo nesta cidade, o qual vem se dando em razão de a regularização fundiária não ser prioridade para os gestores locais. Identificaram-se, também, ineficiência administrativa da Prefeitura no tratamento deste tema; ausência de medidas concretas para a solução deste problema e a falta de fiscalização para evitar a sua ampliação; descontrole sobre o perímetro urbano da cidade e a constatação da contradição entre a necessidade de regularização fundiária urbana periferica e a urbanização da região central da cidade. Como agravante, destacamos a mudança da legislação federal ocorrida em 11 julho de 2017 (Lei nº 13.465), a qual alterou os mecanismos para a regularização fundiária no País, obviamente com reflexos diretos na cidade estudada, tanto pela falta de preparo dos gestores, como pela dificuldade de operacionalizar essa nova lei

Núcleos Urbanos Informais. Projeto e Participação Popular.

O Projeto “Núcleos Urbanos Informais. Projeto e Participação Popular” foi um grande articulador de ações referentes à Regularização Fundiária enquanto extensão universitária durante os anos de 2018 a 2020. O objetivo do Projeto foi realizar a primeira experiência de Regularização Fundiária Urbana -Reurb, com base na nova Lei 13.465/17, do Estado do Tocantins tendo como legitimada uma Associação de Moradores assessorada pela Universidade. O trabalho foi exitoso em todas as etapas, sendo a comunidade contemplada com o decreto municipal de demarcação da área para Regularização

QUADROS DE DELÍRIUM EM PACIENTES DE TERAPIA INTENSIVA E A ASSOCIAÇÃO COM SEDOANALGESIA: UMA REVISÃO BIBLIOGRÁFICA

O delírium é uma alteração do estado cognitivo e mental, de início súbito e usualmente reversível. Os sintomas característicos são alucinações, confusão mental e agitação. São diversos os fatores desencadeantes deste quadro, dentre eles, infecções, idade, abstinência de álcool e drogas, interações medicamentosas e até mesmo a internação em ambiente hospitalar. Existem 2 tipos de delírium, o hipoativo, que é encontrado na maioria dos casos, o paciente se encontra letárgico, prostado, associado principalmente ao idoso, difícil de ser diagnosticado, cursando assim, com um pior prognóstico. O outro tipo de delírium é o hiperativo, associado na grande maioria das vezes em pacientes que se encontram em abstinência de álcool e drogas, o mesmo se encontrará hipervigilante e agressivo, terá um diagnóstico bem explícito, o que contribuirá para a agilidade da introdução do tratamento. O objetivo deste estudo é estabelecer a relação do delirium em pacientes de terapia intensiva com o uso de sedoanalgesia e sugerir meios não farmacológicos que possuem um resultado significante e não invasivo para o tratamento dos pacientes que se encontram com delírum na terapia intensiva. Neste sentido, foi realizada uma revisão de literatura disponível nas bases de dados LILACS, PubMed, Scielo, sem restrição de data de publicação. Foi encontrado que o delirium é uma condição muito comum entre os pacientes hospitalizados na Unidade de Terapia Intensiva (UTI), de forma que o uso de sedoanalgesia mostrou-se bastante associado à ocorrência de delírium, tendo as medidas não farmacológicas um melhor impacto no tratamento. Por fim, é recomendável que sejam conduzidas pesquisas adicionais no futuro, com o intuito de aprofundar nossa compreensão desse problema

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Background: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. Methods: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. Findings: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. Interpretation: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

BACKGROUND: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period. METHODS: 22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution. FINDINGS: Global all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations. INTERPRETATION: Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic. FUNDING: Bill & Melinda Gates Foundation

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. Methods: The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Findings: Global DALYs increased from 2·63 billion (95% UI 2·44–2·85) in 2010 to 2·88 billion (2·64–3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7–17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8–6·3) in 2020 and 7·2% (4·7–10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0–234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7–198·3]), neonatal disorders (186·3 million [162·3–214·9]), and stroke (160·4 million [148·0–171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3–51·7) and for diarrhoeal diseases decreased by 47·0% (39·9–52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0–19·8]), depressive disorders (16·4% [11·9–21·3]), and diabetes (14·0% [10·0–17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7–27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6–63·6) in 2010 to 62·2 years (59·4–64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6–2·9) between 2019 and 2021. Interpretation: Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. Funding: Bill & Melinda Gates Foundation

Catálogo Taxonômico da Fauna do Brasil: setting the baseline knowledge on the animal diversity in Brazil

The limited temporal completeness and taxonomic accuracy of species lists, made available in a traditional manner in scientific publications, has always represented a problem. These lists are invariably limited to a few taxonomic groups and do not represent up-to-date knowledge of all species and classifications. In this context, the Brazilian megadiverse fauna is no exception, and the Catálogo Taxonômico da Fauna do Brasil (CTFB) (http://fauna.jbrj.gov.br/), made public in 2015, represents a database on biodiversity anchored on a list of valid and expertly recognized scientific names of animals in Brazil. The CTFB is updated in near real time by a team of more than 800 specialists. By January 1, 2024, the CTFB compiled 133,691 nominal species, with 125,138 that were considered valid. Most of the valid species were arthropods (82.3%, with more than 102,000 species) and chordates (7.69%, with over 11,000 species). These taxa were followed by a cluster composed of Mollusca (3,567 species), Platyhelminthes (2,292 species), Annelida (1,833 species), and Nematoda (1,447 species). All remaining groups had less than 1,000 species reported in Brazil, with Cnidaria (831 species), Porifera (628 species), Rotifera (606 species), and Bryozoa (520 species) representing those with more than 500 species. Analysis of the CTFB database can facilitate and direct efforts towards the discovery of new species in Brazil, but it is also fundamental in providing the best available list of valid nominal species to users, including those in science, health, conservation efforts, and any initiative involving animals. The importance of the CTFB is evidenced by the elevated number of citations in the scientific literature in diverse areas of biology, law, anthropology, education, forensic science, and veterinary science, among others

Urban struggles for housing: center of São Paulo

A partir dos atuais desdobramentos das práticas dos movimentos de moradia no centro da cidade de São Paulo, este trabalho pretende discutir as formas de espacialização dessas lutas, no que concerne à ampliação do entendimento das conquistas efetivadas por esses movimentos. Para tanto, trabalhou-se em sentido oposto à tese da perda de vitalidade da região central, que em meio aos recentes processos de intervenção urbana demonstrou, na detecção de ambiguidades e encruzilhadas urbanas, sociais e políticas, o surgimento de um novo ciclo de conflituosidades. Para além das questões relativas aos grandes eixos de gentrificação e expulsão das camadas mais empobrecidas do Centro, o contexto estudado revelou situações funcionais de visibilidade e invisibilidade da problemática urbana central. A pesquisa empírica se deparou com processos de resistência e novas formas de relação e negociação entre os atores, em um contexto de esvaziamento da política e das possibilidades de experiência. A relação entre todos os atores na constituição do espaço urbano revela mudanças e disputas repletas de contradições e indistinções - não paradoxais - o que denota relações estruturantes e ao mesmo tempo de resistência.Based on the current developments in the practice of housing movements in the city center of São Paulo, this research intends to discuss the ways of spatialization of these struggles, with regard to increasing the understanding of the achievements effected by these movements. For that, this work took the opposite direction to the thesis of the central region loss of vitality, which amid the recent urban intervention processes, demonstrated in the detection of ambiguities and urban crossroads, social and policies, the emergence of a new cycle of conflicts. Beyond from the issues related to the major axes of gentrification and eviction of the poorest layers of the city center, the context studied revealed functional situations of visibility and invisibility of the central urban problems. The empirical research has met resistance processes and new relationship and negotiation ways between the actors, in a context of the political emptying and of the possibilities of experience. The relation among all the actors in the constitution of the urban space reveals changes and disputes fraught with contradictions and lack of distinction - not paradoxical - which shows structuring relations and, at the same time of resistance

REGULARIZAÇÃO FUNDIÁRIA - NOVA LEI - VELHAS PRÁTICAS: CASO DE ARAGUAÍNA – AMAZÔNIA LEGAL.

O estudo realizado objetivou, a partir da análise em assentamentos humanos de baixa renda, entender a segregação periférica e a expansão urbana na cidade de Araguaína-TO. A metodologia de abordagem qualitativa aplicada ao estudo consistiu na análise de documentos sobre os programas habitacionais e os de regularização fundiária, elaborados pelo Poder Público local. Realizou-se pesquisa de campo nos assentamentos humanos de baixa renda definidos pelo estudo. Este trabalho de campo, que consistiu em entrevistas com as lideranças das ocupações estudadas e com os gestores municipais, teve a finalidade de compreender os modos de ocupação irregular na cidade, pela lógica da demanda por moradia e disputa do espaço urbano, entendido como mercadoria pelo setor imobiliário. Concluiu-se haver problema fundiário complexo nesta cidade, o qual vem se dando em razão de a regularização fundiária não ser prioridade para os gestores locais. Identificaram-se, também, ineficiência administrativa da Prefeitura no tratamento deste tema; ausência de medidas concretas para a solução deste problema e a falta de fiscalização para evitar a sua ampliação; descontrole sobre o perímetro urbano da cidade e a constatação da contradição entre a necessidade de regularização fundiária urbana periferica e a urbanização da região central da cidade. Como agravante, destacamos a mudança da legislação federal ocorrida em 11 julho de 2017 (Lei nº 13.465), a qual alterou os mecanismos para a regularização fundiária no País, obviamente com reflexos diretos na cidade estudada, tanto pela falta de preparo dos gestores, como pela dificuldade de operacionalizar essa nova lei